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Background. Patients diagnosed with metastatic cancer have almost uniformly poor prognoses. The treatments available for
patients with disseminated disease are usually not curative and have side effects that limit the therapy that can be given. A
treatment that is selectively toxic to tumors would maximize the beneficial effects of therapy and minimize side effects,
potentially enabling effective treatment to be administered. Methods and Findings. We postulated that the tumor-tropic
property of stem cells or progenitor cells could be exploited to selectively deliver a therapeutic gene to metastatic solid
tumors, and that expression of an appropriate transgene at tumor loci might mediate cures of metastatic disease. To test this
hypothesis, we injected HB1.F3.C1 cells transduced to express an enzyme that efficiently activates the anti-cancer prodrug
CPT-11 intravenously into mice bearing disseminated neuroblastoma tumors. The HB1.F3.C1 cells migrated selectively to
tumor sites regardless of the size or anatomical location of the tumors. Mice were then treated systemically with CPT-11, and
the efficacy of treatment was monitored. Mice treated with the combination of HB1.F3.C1 cells expressing the CPT-11-
activating enzyme and this prodrug produced tumor-free survival of 100% of the mice for .6 months (P,0.001 compared to
control groups). Conclusions. The novel and significant finding of this study is that it may be possible to exploit the tumor-
tropic property of stem or progenitor cells to mediate effective, tumor-selective therapy for metastatic tumors, for which no
tolerated curative treatments are currently available.
Citation: Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, et al (2006) Development of a Tumor-Selective Approach to Treat Metastatic
Cancer. PLoS ONE 1(1): e23. doi:10.1371/journal.pone.0000023
INTRODUCTION
Neuroblastoma is the most common extracranial solid tumor in
children. Typically, patients diagnosed with high-risk disease
demonstrate a good initial response to therapy, but as many as
80% of these patients relapse with metastatic disease that is
refractory to therapy. Like other solid tumors, when neuroblas-
tomas metastasize, they are very difficult to treat, and a majority of
children with metastatic neuroblastoma die of their disease [1–3].
Currently available treatments have anti-tumor efficacy but they
also produce undesirable side effects to normal tissue, limiting
the treatment that can be administered. Novel and effective
approaches for the treatment of neuroblastoma are needed.
The approach described in this study is based on exploiting the
tumor-tropic property of HB1.F3.C1 cells [4–16] to deliver an
effective therapeutic agent selectively to tumors. The specific goal
of the study was to show that intravenous administration of
HB1.F3.C1 cells expressing the CPT-11 (irinotecan)-activating
enzyme rabbit carboxylesterase (rCE) would significantly increase
the antitumor effect of tolerated doses of CPT-11 in mice bearing
disseminated neuroblastoma tumors. The approach described
might also be adapted to developing treatment for patients with
other types of metastatic solid tumors.
Neural stem cells (NSCs) or progenitor cells (NPCs) and
mesenchymal stem cells (MSCs) have recently been investigated
as delivery vehicles for treating subcutaneous xenografts, as well as
for treating tumors in the central nervous system or lungs of
preclinical models. This is the first study attempting to exploit the
remarkable tumor-tropism of these cells to develop treatments for
metastatic, disseminated solid tumors. Since no effective treat-
ments are available for most metastatic tumors, demonstrating that
stem or progenitor cells of fetal or adult origin can be used to
improve the prognosis of patients with fatal metastatic disease
would be highly significant.
The cell line used in this study (HB1.F3.C1) was derived from
fetal telencephalon cells. Primary cells were immortalized by
retroviral insertion of the v-myc gene which was required to sustain
their replication potential [17]. Following immortalization,
HB1.F3.C1 cells replicate in vitro to form identical daughter cells
or can be induced to differentiate into other cells of neuronal
lineage, thereby exhibiting characteristics of both stem cells and
progenitor cells. Since HB1.F3.C1 cells administered systemically
migrate to and localize in vivo at sites of pathology including
tumors, we proposed to exploit this property to selectively deliver
rCE to activate the anticancer prodrug CPT-11 [18–20]. We
hypothesized that increased conversion of this prodrug to its active
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antitumor activity. We administered intravenously adenovirus-
transduced HB1.F3.C1 cells expressing a secreted form of rCE to
mice bearing disseminated neuroblastoma. Mice were then treated
systemically with CPT-11 and long-term survival of animals was
monitored. The results obtained suggest that novel enzyme/
prodrug approaches to therapy using stem or progenitor cells as
delivery vehicles may have utility in the treatment of metastatic
cancer.
METHODS
Tumor Cell Lines
The three human neuroblastoma cell lines used in this study were
NB-1691, NB-1643, and SK-N-AS [21,22]. These cell lines were
obtained from the Pediatric Oncology Group and the American
Type Culture Collection and reflect different neuroblastoma
phenotypes and genotypes: N-myc amplified, N-myc non-amplified/
overexpressed, N-myc non-amplified/low level expression, MDM2
amplified, and different ratios of nuclear/cytoplasmic p53. Each
type of experiment detailed below was done with all three cell
lines; results from representative experiments are shown. Three
neuroblastoma cell lines were used to show that results observed
were not limited to a single cell line; similar results were observed
with all three cell lines. Tumor cell lines were grown in DMEM
containing 10% FCS at 37uC in a humidified atmosphere
containing 10% CO2.
HB1.F3.C1 Cell Line
The HB1.F3.C1 cell line is a multipotent, cloned cell line that was
generated by immortalizing cells obtained from the telencephalon
of a human fetus of 15 weeks’ gestation, using a retrovirus
encoding the v-myc gene [17,23]. The primary cells were obtained
in accordance with the Guidelines of the Anatomical Pathology
Department of Vancouver General Hospital, with permission to
use fetal tissue granted by the Clinical Research Screening
Committee Involving Human Subjects of the University of British
Columbia. HB1.F3.C1 is an established, well-characterized, stable
cell line [23–27]. HB1.F3.C1 cells self-renew in vitro, are non-
tumorigenic, and are multipotent in that they can be induced to
differentiate into neurons, oligodendrocytes, and astrocytes [17].
The use of this cell line circumvented the significant problem of
limited availability of large quantities of primary cells and
maximized reproducibility among experiments. The cell line was
grown in DMEM with 10% FCS at 37uC in a humidified
atmosphere of 10% CO2.
Transduction of HB1.F3.C1 Cells to Express rCE
Replication-deficient adenovirus expressing a secreted form of
rCE under the control of the cytomegalovirus (CMV) promoter
(AdCMVrCE) was constructed using standard methods, as
described previously [18,20,28]. HB1.F3.C1 cells were co-cultured
with AdCMVrCE for 24 hours prior to intravenous injection. The
enzyme activity assay used to quantitate the level of expression of
rCE by HB1.F3.C1 cells transduced with adenovirus has also been
reported previously [20].
HB1.F3.C1 Cell Migration, Injection and Localization
To examine whether HB1.F3.C1 cells, injected intravenously,
migrate to disseminated tumor foci in mice, neuroblastoma tumor
cells were injected intravenously into the tail veins of mice and
allowed to seed and develop tumors for two months. HB1.F3.C1
cells (2610
6) were then injected via the same route and organs
were harvested 3–4 days later to evaluate migration to macro-
scopic and microscopic tumors.
For therapeutic experiments, HB1.F3.C1 cells were adminis-
tered 2 weeks following injection of neuroblastoma cells. At this
time point, tumors are microscopic and undetectable by eye or by
in vivo imaging. Consistent with initiating treatment at this time
point, we propose that the most likely eventual clinical utility of the
described approach will be to eradicate minimum residual disease
following conventional therapy. This experimental protocol most
directly reflects that potential application.
In both migration and therapeutic studies, 2610
6 HB1.F3.C1
cells transduced with adenovirus at a multiplicity of infection
(MOI) of 20 were pre-labeled with CM-DiI (chloromethylbenza-
mido-1,19-dioctadecyl-3,3,39,39-tetramethylindocarbocyanine per-
chlorate, Molecular Probes, Eugene, OR) according to manufac-
turer’s instructions. Cells were then rinsed 3 times with PBS and
injected into the tail vein of tumor-bearing mice. CM-DiI was
chosen because it is non-diffusible by virtue of its covalent binding
to cellular thiols, and has been shown to be suitable for labeling
and in vivo tracking of cells for at least 10 weeks [29,30]. In
experiments included in this paper, mice injected with CM-DiI-
labeled cells were harvested 3–4 days following labeling and
injection.
Es1
e Esterase-deficient Severe Combined
Immunodeficient (SCID) Mice
The plasma of SCID mice contains high levels of a rodent
carboxylesterase that activates CPT-11 [31,32]. Therefore, we
used esterase-deficient SCID mice for all in vivo therapeutic studies
[33]. These animals have levels of plasma esterase comparable to
those in human plasma. Mice were housed in an AALAAC-
accredited facility and were given food and water ad libitum.
RT-PCR/PCR
Bone marrow was harvested from the tibia of normal and tumor-
bearing mice, and RNA was extracted for RT-PCR detection of
tyrosine hydroxylase (TH), a neuroblastoma cell marker. DNA was
extracted from a separate aliquot of bone marrow for PCR of the
v-myc gene to identify HB1.F3.C1 cells. Primer sequences and
RT-PCR conditions for TH have been published previously [21].
Standard methods were used for v-myc amplification using a
forward primer of 59-CCTTTGTTGATTTCGCCAAT-39 and
a reverse primer of 59-AGTTCTCCTCCTCCTCCTCG-39, with
an annealing step of 62.5uC for 1 minute for 30 cycles. The
positive control for TH was RNA extracted from NB-1691 cells,
and for the v-myc gene was DNA from HB1.F3.C1 cells.
Negative controls contained no RT or no DNA, for TH and
v-myc reactions, respectively.
Histochemistry, Immunohistochemistry and
Immunofluorescence Imaging
Organs were harvested, fixed in 4% paraformaldehyde/PBS,
pH 7.4 and cryoprotected in 30% sucrose. Fixed tissues were then
embedded in OCT, serially cryosectioned (10 mm), thaw-mounted
onto glass slides and stored dry at 220uC. For routine histological
screening, tissue sections were stained with hematoxylin and eosin
by standard methods.
Presence of HB1.F3.C1 cells at neuroblastoma tumor loci or
in normal tissue was examined using fluorescence microscopy. In
sections prepared as detailed above, nuclei of all cells were stained
with DAPI (49,6-diamidino-2-phenylindole; Sigma Biochemical,
St. Louis, MO; blue fluorescence), and detected using epifluores-
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2A, Nikon). HB1.F3.C1 cells, labeled with CM-DiI (red
fluorescence), were detected using excitation/emission filters of
540–580 nm and 600–660 nm (Y-2E/C), using a Nikon Eclipse
TE2000-U microscope (Nikon Instruments, Melville, NY)
equipped with a SPOT RT Slider digital camera (Diagnostic
Instruments, Sterling Heights, MI). To detect human neuroblas-
toma tumors in mouse tissues, we performed immunohistochem-
ical staining using a mouse monoclonal antibody that recognizes
human mitochondrial protein (Chemicon, Temecula, CA).
Sections were post-fixed in 4% paraformaldehyde for 10 min,
rinsed, permeabilized with 0.3% Triton X-100/PBS, 30 min and
incubated in blocking solution (5% BSA+3% normal horse
serum+0.1% Triton X-100, 1 h). Sections were then incubated
sequentially with primary antibody (1:100 dilution) for 16 h at
4uC, biotinylated anti-mouse IgG secondary antibody (Vector
Laboratories, Burlingame, CA) for 2 hours, and avidin-FITC
(Vector Laboratories) for 1 hour. Tissue sections were counter-
stained with DAPI and mounted with fluorescent mounting
medium (DAKO). The FITC fluorescence was detected by
epifluorescence filter (465–495 nm excitation, 515–555 nm emis-
sion; B-2E/C).
For routine histological evaluation of presence of tumors in
various organs, tissue sections were stained with hematoxylin and
eosin. Adjacent sections were processed for immunoperoxidase-
3,39-diaminobenzidine (DAB) staining similarly as tissues pro-
cessed for fluorescence staining, except that after permeabilization,
endogenous peroxidases were quenched with 0.3% hydrogen
peroxide/PBS for 30 min. Antibody reactivity to human mito-
chondria was subsequently detected using a Vectastain ABC Elite
kit (Vector Laboratories) and a Peroxidase Substrate Kit (Vector
Laboratories) according to the manufacturer’s directions.
Low- and high-magnification images were obtained using a
Nikon Eclipse TE2000-U microscope (Nikon Instruments, Mel-
ville, NY) equipped with brightfield and fluorescence illumination.
Images were recorded and stored using SPOT Advanced and
Adobe Photoshop software.
Modified Boyden Chamber Cell Migration Assay
Modified Boyden chamber assays were used to assess the in vitro
tropism of HB1.F3.C1 cells to tumor cell-conditioned media or to
control media, using standard methods. Briefly, HB1.F3.C1 cells
transduced with a MOI of 0, 5, 10 or 20 AdCMVrCE were
trypsinized, washed, and resuspended in DMEM containing 5%
BSA. Cells (3610
4 cells/100 ml) were placed into upper chambers
and neuroblastoma cell-conditioned medium in lower chambers.
Neuroblastoma cell-conditioned medium in both the upper and
lower chambers comprised the chemokinesis control without
a chemoattractant gradient. Cells were allowed to migrate for
4 hours in a cell culture incubator at 37uC and 5% CO2. The
number of migrated HB1.F3.C1 cells in the lower chamber of
each well was quantitated using CyQuant GR fluorescent dye
(Chemicon) and a fluorescence microplate reader (Molecular
Devices, Sunnyvale, CA). Assays were performed in triplicate.
Animal Studies
Disseminated neuroblastoma was produced by injecting 5610
5
NB-1691, NB-1643, or SK-N-AS cells into the tail veins of mice.
Typically these mice require euthanasia ,75 days following
injection of neuroblastoma cells. Gross tumors in multiple organs
are visible at necropsy. This metastatic neuroblastoma model has
been well characterized and is highly reproducible with regard to
the course of disease and organ involvement [34]. In addition, the
model recapitulates the clinical pattern of metastatic neuroblasto-
ma in that tumors develop in multiple loci, including the adrenal
gland, bone marrow and liver.
Each treatment group included 10 mice, monitored daily for the
presence of disease or ill health. The weekly schedule of
administration of HB1.F3.C1 cells and CPT-11 (7.5 mg/kg) is
illustrated in Figure 8. This regimen was administered for 2
consecutive weeks, followed by a 2-week rest period and then
another 2-week course of therapy. All animal protocols were
approved by the City of Hope or the St. Jude Children’s Research
Hospital IACUC. When mice appeared to be in discomfort or
distress as judged by independent animal care personnel with no
knowledge of the protocol design, animals were euthanized. All
euthanized mice were verified as tumor-bearing by necropsy. The
endpoint for the therapeutic study was long-term survival.
Statistical Analyses
All data were analyzed with GraphPad Prism software (San Diego,
CA). Analyses of cell migration results (mean cell number6-
S.E.M.) of untransduced cells were compared to that of cells
transduced with adenovirus. These data were analyzed using
a two-tailed t-test. Analysis of Kaplan-Meier plots compared
survival of 10 mice per group using a log-rank (Mantel-Haenszel)
method.
RESULTS
Mouse Model of Metastatic Neuroblastoma
Intravenous injection of 5610
5 NB-1691, NB-1643, or SK-N-AS
human neuroblastoma cells produces disseminated neuroblastoma
in 100% of esterase-deficient SCID mice. The disseminated nature
of tumors is evident in Figure 1 in two mice that received tail vein
injections of SK-N-AS cells transduced to express luciferase. One
Figure 1. Es1
e SCID mice injected intravenously with neuroblastoma
cells develop multiple disseminated tumors. SK-N-AS cells (5610
5)
transduced to express luciferase were injected into tail veins. One
month following injection of tumor cells, mice were injected in-
traperitoneally with luciferin and imaged using a Xenogen IVIS imaging
system, according the directions of the manufacturer. Multiple tumors
were present in 100% of mice. Two representative mice are shown.
doi:10.1371/journal.pone.0000023.g001
Treatment of Metastatic Cancer
PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e23month following injection of neuroblastoma cells, the luciferase
substrate luciferin was injected intraperitoneally to visualize
tumors in situ. Consistent with published reports, tumors were
present in multiple organs and anatomical locations including
abdomen, bone marrow, liver, and lungs [21,34]. Since 100% of
mice injected with neuroblastoma cells develop disseminated
disease that ultimately results in death, this model facilitated
evaluation of therapeutic experiments which were conducted
according to the schema in Figure 2. This Figure illustrates the
hypothesis to be tested. Mice injected with human neuroblastoma
cells develop multiple tumors. Two weeks following injection of
neuroblastoma cells, HB1.F3.C1 cells transduced with adenovirus
encoding a prodrug-activating enzyme are administered intrave-
nously. Three days later, after HB1.F3.C1 cells have localized
preferentially to tumor sites and the prodrug-activating enzyme
(rCE in this study) is expressed at high levels, prodrug (CPT-11)
administration is initiated, given on a predetermined optimal
schedule. The antitumor efficacy of prodrug alone can then be
compared with co-administration of HB1.F3.C1 cells and
prodrug, using survival as an endpoint.
Localization of HB.F3.C1 Cells to Neuroblastoma
Tumor in Liver
To first confirm that HB1.F3.C1 cells migrate to and localize at
disseminated neuroblastoma tumors, mice with established NB-
1643 tumors were injected intravenously with 2610
6 CM-DiI
labeled HB1.F3.C1 cells. After 3 days, normal and tumor-bearing
organs were harvested and sectioned, and evaluated microscop-
ically. As shown in Figure 3, multiple tumors were evident by gross
inspection in the liver of a representative mouse (panel A), and also
by microscopic evaluation of hematoxylin/eosin stained sections
(panels B and C, purple areas) and immunoperoxidase staining for
human mitochondrial protein (panel D, brown areas). HB1.F3.C1
cells co-localized with these tumor foci, as demonstrated by the
CM-DiI-labeled, red cells seen in panel E. This panel also shows
extravasation of the HB1.F3.C1 cells and their migration away
from the hepatic vein (v). Panel F shows HB1.F3.C1 NSCs (CM-
DiI-labeled, red) and panel G shows same section stained with
human mitochondrial antibody-FITC (human NSCs and tumor
cells, green). Panel H, an overlay of panels F and G, demonstrates
co-localization of HB1.F3.C1 cells (orange/yellow, indicated by
white arrows) and tumor cells (green), at sites immediately adjacent
to and distant from the blood vessel (bv). Similar results were
observed for tumors in multiple other organs including the ovary
(not shown) and bone marrow (Figure 4).
HB1.F3.C1 Cells Localize to Neuroblastoma
Metastases in Bone Marrow
Since bone marrow is a frequent site of neuroblastoma metastasis
and marrow aspirates or biopsies are used to document the stage
of the disease in high-risk patients, we sought to determine
whether HB1.F3.C1 cells also infiltrated tumors at this site. The
left panel of Figure 4 shows the x-ray of the femur of mouse
bearing a macroscopic tumor that originated in the bone marrow.
This animal was injected intravenously with CM-DiI-labeled
HB1.F3.C1 cells and euthanized three days later. The area of the
bone indicated by the red rectangle was then processed for
immunofluorescence microscopy. The right panel of Figure 4
clearly shows HB1.F3.C1 cells (red fluorescence) infiltrating the
tumor-bearing marrow, documenting that these cells migrated to
and co-localized with macroscopic tumors (Figure 4) as well as
microscopic tumors (Figure 3). However, while interesting, we
considered it more important and relevant to demonstrate
migration of HB1.F3.C1 cells to microscopic tumors in bone
marrow (Figure 5), as disease at relapse is thought to originate
from residual tumor cells present in the marrow or at primary
sites. Also, it is essential to the successful clinical application of this
approach to show that HB1.F3.C1 cells are not present in normal
tissue (Figures 5, 6).
Molecular Evidence for HB1.F3.C1 Cell and Tumor
Cell Co-localization in Bone Marrow
To address the first of these two questions, we evaluated migration
of HB1.F3.C1 cells to tumor cells in bone marrow, using a sensitive
molecular approach to detect the presence of minimal numbers of
tumors cells and/or HB1.F3.C1 cells. To this end, we harvested
marrow from mice that had been injected intravenously with NB-
1691 cells, followed by HB1.F3.C1 cells two weeks later. As noted
above, at this ‘‘stage’’ of disease, tumors are not detectable
microscopically. We then used PCR to detect the v-myc gene
present in HB1.F3.C1 cells and RT-PCR to detect tyrosine
hydroxylase (TH), a neuroblastoma cell marker. Data in Figure 5
show that either both v-myc and TH or neither of these markers
were detected in any given marrow. If the marrow contained
tumor cells as indicated by a detectable signal for TH, HB1.F3.C1
cells (a positive signal for v-myc) were also present. Conversely,
when no neuroblastoma cells were detected, HB1.F3.C1 cells were
similarly undetectable. This ‘‘co-localization’’ occurred within 1 hr
after injection and persisted for at least 7 days. These data are
consistent with results in Figures 3 and 4, and show that
HB1.F3.C1 cells rapidly migrate to tumor cells in vivo.
Few HB1.F3.C1 Cells are Present in Normal Tissue
For therapy to be tumor-selective, it was also essential to show that
HB1.F3.C1 cells did not migrate to other normal tissues.
Accordingly, 2610
6 CM-DiI-labeled cells were injected intrave-
nously into mice bearing NB-1643 tumors and after 3 days, all
organs were harvested and evaluated for the presence of
HB1.F3.C1 cells. Figure 6 demonstrates that few, if any,
HB1.F3.C1 cells were present in normal brain, kidney, heart,
Figure 2. Schematic diagram of the protocol for NDEPT. Human
neuroblastoma tumor cells are injected intravenously to produce
disseminated tumors. At an appropriate time after injection of
neuroblastoma cells, neural stem cells or neural progenitor cells
transduced with adenovirus to express a prodrug-activating enzyme
(in this study, a secreted form of rabbit carboxylesterase [rCE]) are
injected intravenously. Following migration of stem cells or progenitor
cells to tumor foci and a delay of 3–4 days to allow relatively high level
expression of the prodrug-activating enzyme into the extracellular
milieu at the tumor sites, mice are treated with the prodrug (in this
study, CPT-11). The prodrug is activated selectively at tumor foci, to
increase the therapeutic index of the prodrug.
doi:10.1371/journal.pone.0000023.g002
Treatment of Metastatic Cancer
PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e23intestine or skin tissue (panels A–E, respectively). Occasionally,
a single cell was observed in the lung, liver or spleen (panels F–H,
respectively), but no focus of CM-DiI fluorescence was seen in any
normal tissue of any of five mice examined. We concluded that the
HB1.F3.C1 cells migrated selectively to neuroblastoma cells
following intravenous injection.
Therapeutic Efficacy for Treatment of Metastatic
Neuroblastoma
Having established that HB1.F3.C1 cells are tumor-tropic in vivo,
we evaluated the antitumor efficacy of our neural stem/progenitor
cell-directed enzyme prodrug (NDEPT) approach to therapy,
using HB1.F3.C1 cells transduced to express a secreted form of
a rabbit carboxylesterase (rCE) and the anticancer prodrug CPT-
11. We first confirmed, using modified Boyden chamber assays,
that adenoviral transduction and expression of rCE did not alter
the tropic properties of the HB1.F3.C1 cells (Figure 7). We also
determined that the maximal level of expression of rCE occurred
3–4 days following transduction (data not shown). We then
transduced HB1.F3.C1 cells with replication-deficient adenovirus
encoding rCE, and injected intravenously the transduced cells
into mice bearing disseminated SK-N-AS tumors. Mice were
treated according to the protocol shown schematically in Figure 8.
As shown in the Figure, four days following injection of
HB1.F3.C1+AdCMVrCE cells (three days following injection of
HB1.F3.C1 cells), we initiated treatment with CPT-11 (7.5 mg/kg)
on a daily 65 schedule, an optimal schedule of administration for
patients with neuroblastoma. This treatment was repeated the
following week, followed by a 2-week rest period and then another
2-week course of therapy. The Kaplan-Meier graph in Figure 9
shows survival data of untreated mice compared with mice treated
Figure 3. HB1.F3.C1 cells injected intravenously localize to micrometastatic human NB-1643 neuroblastoma tumors in the liver of a mouse. (A)
Dissected liver from a representative animal with hepatic metastases; the animal was sacrificed two days following injection of HB1.F3.C1 cells into
the tail vein. (B) Low- and (C) high-power magnification of a section of tumor-involved liver, stained with hematoxylin and eosin. Tumor cells appear
dark purple (black arrows); normal tissue appears pink. (D) Liver section stained with an anti-human mitochondrial protein antibody and
counterstained with hematoxylin. Tumor micrometastases stain dark brown (red arrows); normal liver tissue is purple. (E) Immunofluorescence
microscopy of liver section. HB1.F3.C1 cells were CM-DiI-labeled prior to injection and are evident as red cells. The liver section was stained with DAPI;
tumor foci are identified by areas of densely-packed DAPI-stained tumor cell nuclei. The red arrows show extravasated HB1.F3.C1 cells proximal to
a hepatic vein (v). Inset is high magnification of a DiI-labeled HB1.F3.C1 cell within the tumor. (F–H) Liver section from a tumor-bearing animal that
received CM-DiI-labeled HB1.F3.C1 cells was stained with FITC-conjugated human specific mitochondrial antibody. (F) Red CM-DiI-labeled HB1.F3.C1
cells. (G) The same section showing FITC-labeled (green) human tumor cells and HB1.F3.C1 cells. (H) Overlay of F (red CM-DiI HB1.F3.C1 cells) and G
(green FITC HB1.F3.C1 and tumor cells). HB1.F3.C1 cells (orange/yellow cells indicated by white arrows) migrated to hepatic micrometastases (green
cells) and infiltrated the tumor parenchyma in the proximity of a blood vessel (bv, white dotted lines). Scale bars: 1 cm (A), 2 mm (B), 500 mm (C),
200 mm (F, G), 100 mm (D, E, H), 10 mm (E inset).
doi:10.1371/journal.pone.0000023.g003
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expressing rCE and CPT-11. As expected, untreated animals
required euthanasia between days 36 and 77 (median 63 days).
CPT-11 treatment alone had some antitumor efficacy, with 50%
of this group of animals surviving for the 6-month observation
period (median survival 169 days, P,0.0001 compared to
untreated animals). In contrast, 100% of mice treated with rCE/
CPT-11 NDEPT, survived without evidence of disease (P,0.001
and 0.001, compared to CPT-11 alone or to untreated mice,
respectively). These results are consistent with the hypothesis that
enhanced drug activation occurred at the disseminated tumor loci
within these animals, increasing the anti-tumor efficacy of the
CPT-11 and prolonging disease-free survival.
DISCUSSION
This report is the first to show that undifferentiated cells of neural
origin may have utility for targeted treatment of metastatic solid
tumors. The described approach relies upon the tumor-tropic
property of the HB1.F3.C1 cell line to selectively deliver a prodrug
activating enzyme (rCE) to metastatic foci. We propose that when
the prodrug (in this instance, CPT-11) is administered systemically,
it is preferentially activated at tumor sites leading to high local
concentrations of the cytotoxic metabolite and tumor cell death.
We evaluated this approach using a preclinical mouse model of the
pediatric tumor neuroblastoma, and showed that 100% of animals
receiving the described treatment were alive and well 6 months
following therapy. Importantly, the approach we describe should
be readily translatable into clinical studies, since the dose and
schedule of administration of CPT-11 (and the plasma level of
active metabolite produced) used in these preclinical experiments
are tolerated by patients [35]. We propose that similar methodo-
logy may be effective for other types of metastatic tumors,
provided the most appropriate stem or progenitor cells are used to
deliver therapeutic transgenes that target specific tumor types.
The HB1.F3.C1 cell line used in these studies was derived from
the neural cells of the telencephalon of a human fetus of 15 weeks9
gestation, in accordance with the Guidelines for Use of Human
TissueoftheUniversityofBritishColumbia [23].Tomaintainthese
cells in culture, they were immortalized by retrovirus-mediated
transduction with the v-myc gene. The transduced cell line is non-
tumorigenic, as determined by anchorage-independent growth in
soft agar or tumor formation in immune-deprived mice [17,25].
The exact molecular basis of the tumor-tropism of the F3.C1 line or
other stem/progenitor cells, is not well understood, but factors such
as stromal cell-derived factor-1 (SDF-1; CXCL12), scatter factor
(SCF; HGF), vascular endothelial growth factor (VEGF) and
macrophage chemotactic protein-1 (MCP-1) expressed by tumor
cells likely play a chemotactic role [15,36–42]. Although the
mechanism by which HB1.F3.C1 cells target neuroblastoma cells is
largely unknown, it is clear that this tropism is not cell line specific
since these cells migrated to NB-1643 liver metastases (Figure 3),
NB-1691 minimal bone marrow disease (Figure 5), and SK-N-AS
macroscopic bone marrow tumors (Figure 4). Studies designed to
evaluate the mechanism of tumor cell recognition by stem or
progenitor cells are ongoing in our laboratories.
Figure 4. HB1.F3.C1 cells target macroscopic metastatic neuroblastoma in the bone marrow. X-ray image of hind limb of a mouse with advanced
stage neuroblastoma (Day 82; left panel, scale bar: 1 cm). Confirmation of the tumor mass as human SK-N-AS neuroblastoma cells was performed by
immunohistochemistry using anti-human mitochondria antibody (not shown). The CM-DiI-labeled HB1.F3.C1 cells (red cells, injected into the tail vein
3 days prior to sacrifice) localized to tumor in the marrow (right panel; scale bar: 200 mm).
doi:10.1371/journal.pone.0000023.g004
Figure 5. HB1.F3.C1 cells injected intravenously localized to microscopic
bone marrow disease. Concordant detection of v-myc (HB1.F3.C1 cells)
by PCR and TH expression (neuroblastoma cells) by RT-PCR in bone
marrow specimens. Bone marrow samples isolated from animals
injected with HB1.F3.C1 cells were analyzed for the presence of v-myc
(HB1.F3.C1 cells) or the expression of TH (NB-1643 cells). HB1.F3.C1 cells
were present in the bone marrow only when tumor cells were also
present. HB1.F3.C1 cells were not detected in the bone marrow of non-
tumor-bearing animals. The positive controls (+) were DNA extracted
from HB1.F3.C1 cells for v-myc, and RNA extracted from NB-1691 cells
for TH. The negative controls (2) contained no DNA or RNA template,
respectively.
doi:10.1371/journal.pone.0000023.g005
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delivery vehicles, to deliver interferon-b to animal models of
MDA-231 breast cancer nodules in the lung [14]. Two concerns
that must be addressed before the type of approach described in
that study can be incorporated into clinical trials are, first, that
MSCs continue to replicate in vivo and also incorporate into tumor
stroma, constituting a significant fraction of the stromal tissue and
possibly supporting tumor growth [43,44]. In contrast, HB1.F3.C1
cells do not replicate in vivo and undergo apoptosis in normal tissue
[4,45]. HB1.F3.C1 cells also differ from bone marrow-derived
MSCs in that MSCs engraft in the marrow of recipients [46],
whereas HB1.F3.C1 cells were detectable in marrow only if tumor
Figure 6. Mice bearing microscopic NB-1643 tumors were injected intravenously with 2 million HB1.F3.C1 cells pre-labeled with CM-DiI Red Cell
Tracker. Normal and tumor-bearing organs were harvested, sectioned, and stained with DAPI. HB1.F3.C1 cells were not detected in normal (A) brain,
(B) kidney, (C) heart, (D) intestine, or (E) skin tissue. Rare, single, HB1.F3.C1 cells (white arrows) were seen in (F) lung, (G) liver and (H) spleen. Scale
bars: 200 mm (A–E), 100 mm (F–H).
doi:10.1371/journal.pone.0000023.g006
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migrate to subcutaneous xenografts of numerous solid tumors
including prostate, breast, melanoma, glioma, and neuroblastoma
(Aboody et al., unpublished observations). These results suggest
that this type of undifferentiated cell of neural origin may be
preferable to MSCs when relatively short-term survival of stem/
progenitor cells is desirable such as for cancer therapy, and that
cells or cell lines similar to HB1.F3.C1 cells may have significant
utility for the treatment of metastatic tumors of different
histotypes.
The second concern regarding the MSC-mediated therapy with
interferon-b is that expression of this transgene increased the
median survival of mice from 36 to 60 days. While this was
a significant increase, no cures were attained and the duration of
survival, even in treated animals, was limited. In contrast, data
presented in the current study show that HB1.F3.C1 cell-mediated
delivery of an efficient prodrug-activating enzyme produced
6-month disease-free survival in 100% of mice, compared to 0%
survival of less than 2 months for untreated mice. This observation
emphasizes the necessity for careful selection of the transgene to be
delivered to treat a specific tumor type. Our approach using
HB1.F3.C1 cells expressing rCE to activate CPT-11 at the tumor
site, effectively increasing the therapeutic index of the drug, was
based in part on the encouraging but non-curative activity of
CPT-11 in early clinical trials of children with neuroblastoma and
in part on the inefficient activation of CPT-11 by human enzymes.
Since establishment of the HB1.F3.C1 cell line, it has become
clear that stem/progenitor cells can be harvested from many
fetal and adult tissues. While published data suggest that the
immunogenic potential of cells from allogeneic sources may be
minimal [47], further studies are necessary before clinical trials can
be initiated. If immunogenicity is determined to be problematic,
Figure 7. HB1.F3.C1 cells transduced with an adenoviral multiplicity of infection of 5, 10, or 20 retain their tumor-tropism toward conditioned
medium from SK-N-AS neuroblastoma cells. Bars represent the average number of migrated cells6SEM of triplicate wells in modified Boyden
chamber assays.
doi:10.1371/journal.pone.0000023.g007
Figure 8. Treatment protocol of HB1.F3.C1/AdCMVrCE/CPT-11 NDEPT. One day prior to being used in treatments, cells were transduced with the
AdCMVrCE construct (see text). The treatment schedule was based on the time-course of expression of the secreted form of rCE, following adenoviral
transduction of HB1.F3.C1 cells (Danks, unpublished observation) and on a schedule of administration of CPT-11 that has been shown to be relatively
effective for neuroblastoma patients [35].
doi:10.1371/journal.pone.0000023.g008
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during which viable cells are present in vivo would circumvent
immune-related limitations of the described approach. Alterna-
tively, it may be possible to identify autologous sources of stem/
progenitor cells, such as excess adipose tissue, that could be used
for clinical applications.
The prodrug used in this study, CPT-11, is relatively effective
for the treatment of many solid tumors including neuroblastoma
[35]. Our results demonstrate that the anti-tumor efficacy of CPT-
11 was significantly increased when this prodrug was used as
a component of NDEPT. Since CPT-11 is effective in the
treatment of colon cancer, a logical follow-up study would be to
evaluate the anti-tumor efficacy of rCE/CPT-11 NDEPT in
a model of residual colon cancer, or of hepatic metastases of this
disease. As the level of SN-38 (active metabolite of CPT-11) that is
tolerated by patients is known, doses of CPT-11 in preclinical
experiments can be restricted to those that produce clinically
tolerated levels of SN-38. Such studies may yield results that are
readily translated to clinical applications.
Lastly, we propose that NDEPT will have the greatest
therapeutic efficacy as an adjuvant treatment to eradicate
minimum residual disease, rather than as an initial treatment for
reducing bulk tumor volume. This hypothesis reflects both the
current paucity of information regarding what ratios of stem or
progenitor cells/tumor size are required to attain complete tumor
regressions and what ratios are achievable in vivo. Furthermore,
clinical experience shows that at diagnosis, surgery, chemotherapy,
radiation, and bone marrow transplantation are relatively effective
even in high-risk neuroblastoma patients. Therefore, we propose
that the most logical application of this methodology is during the
window in which patients are apparently free from residual
disease, but who, based on prognostic indicators, will relapse with
metastatic tumors. NDEPT may be a viable option for eradicating
undetectable, residual disease. If successful, this treatment might
significantly improve the long-term survival of patients diagnosed
with high-risk neuroblastoma.
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